K. Kleber

669 total citations
8 papers, 531 citations indexed

About

K. Kleber is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, K. Kleber has authored 8 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hepatology, 6 papers in Epidemiology and 5 papers in Infectious Diseases. Recurrent topics in K. Kleber's work include Hepatitis C virus research (7 papers), Hepatitis B Virus Studies (6 papers) and HIV/AIDS drug development and treatment (5 papers). K. Kleber is often cited by papers focused on Hepatitis C virus research (7 papers), Hepatitis B Virus Studies (6 papers) and HIV/AIDS drug development and treatment (5 papers). K. Kleber collaborates with scholars based in United States, Germany and France. K. Kleber's co-authors include Carol Brosgart, Paul Martin, Peter Buggisch, Ramin Ebrahimi, Marion G. Peters, Mark Sullivan, Christian Trépo, DF Gray, Kris V. Kowdley and Marc Bourlière and has published in prestigious journals such as Gastroenterology, Journal of Hepatology and Journal of Pediatric Gastroenterology and Nutrition.

In The Last Decade

K. Kleber

8 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Kleber United States 5 513 513 129 11 9 8 531
A.R. Türkyilmaz Türkiye 9 368 0.7× 359 0.7× 67 0.5× 11 1.0× 14 1.6× 15 394
S. Xiong China 7 606 1.2× 585 1.1× 144 1.1× 7 0.6× 18 2.0× 15 635
Cecilia Marrocco Italy 11 454 0.9× 466 0.9× 65 0.5× 11 1.0× 9 1.0× 15 500
Karl‐Georg Simon Germany 11 515 1.0× 519 1.0× 85 0.7× 8 0.7× 5 0.6× 33 550
Beatriz Calle Serrano Germany 7 568 1.1× 561 1.1× 51 0.4× 24 2.2× 16 1.8× 9 605
K. Klesczewski United States 7 514 1.0× 505 1.0× 82 0.6× 4 0.4× 7 0.8× 10 546
Guangbi Yao China 10 941 1.8× 912 1.8× 125 1.0× 14 1.3× 17 1.9× 16 972
T. Santantonio Italy 8 656 1.3× 677 1.3× 74 0.6× 22 2.0× 11 1.2× 17 709
Shigeru Yotsumoto Japan 8 382 0.7× 372 0.7× 60 0.5× 13 1.2× 11 1.2× 11 415
A. Guastadisegni Italy 5 477 0.9× 487 0.9× 63 0.5× 13 1.2× 10 1.1× 10 504

Countries citing papers authored by K. Kleber

Since Specialization
Citations

This map shows the geographic impact of K. Kleber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Kleber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Kleber more than expected).

Fields of papers citing papers by K. Kleber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Kleber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Kleber. The network helps show where K. Kleber may publish in the future.

Co-authorship network of co-authors of K. Kleber

This figure shows the co-authorship network connecting the top 25 collaborators of K. Kleber. A scholar is included among the top collaborators of K. Kleber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Kleber. K. Kleber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Läwitz, E., Ziad Younes, J. Santoro, et al.. (2007). [14] CLEARANCE OF HCVRNA WITH VALOPICITABINE (NM) PLUS PEG-INTERFERON IN TREATMENT-NAIVE PATIENTS WITH HCV-1 INFECTION: RESULTS AT 24 AND 48 WEEKS. Journal of Hepatology. 46. S9–S9. 26 indexed citations
2.
Dieterich, Doug, E. Läwitz, Ziad Younes, et al.. (2006). 736 Early clearance of HCV RNA with valopicitabine (NM283) plus PEG-Interferon in treatment-naïve patients with HCV-1 infection: First results from a phase IIb trial. Journal of Hepatology. 44. S271–S272. 34 indexed citations
3.
Sokal, Étienne, D. Kelly, S. Wirth, et al.. (2004). P1202 THE PHARMACOKINETICS (PK) AND SAFETY OF A SINGLE DOSE OF ADEFOVIR DIPIVOXIL (ADV) IN CHILDREN AND ADOLESCENTS (AGED 2–17) WITH CHRONIC HEPATITIS B. Journal of Pediatric Gastroenterology and Nutrition. 39(2). 226–227. 1 indexed citations
4.
Sokal, Étienne, D. Kelly, S. Wirth, et al.. (2004). 445 The pharmacokinetics (PK) and safety of a single dose of adefovir dipivoxil (ADV) in children and adolescents (aged 2–17) with chronic hepatitis B. Journal of Hepatology. 40. 132–132. 4 indexed citations
5.
Peters, Marion G., Hie‐Won Hann, Paul Martin, et al.. (2003). Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).. Gastroenterology. 126(1). 91–101. 440 indexed citations
6.
7.
Zoulim, Fabien, Christian Trépo, Thierry Poynard, et al.. (2003). Adefovir dipivoxil (ADV) for the treatment of patients with chronic hepatitis B (CHB) failing lamivudine (LAM) therapy. Journal of Hepatology. 38. 184–184. 4 indexed citations
8.
Peters, Marion G., Paul Martin, E. Jenny Heathcote, et al.. (2002). Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis. Journal of Hepatology. 36. 6–7. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A.R. Türkyilmaz Breakdown of academic impact, for papers by S. Xiong Breakdown of academic impact, for papers by Cecilia Marrocco Breakdown of academic impact, for papers by Karl‐Georg Simon Breakdown of academic impact, for papers by Beatriz Calle Serrano Breakdown of academic impact, for papers by K. Klesczewski Breakdown of academic impact, for papers by Guangbi Yao Breakdown of academic impact, for papers by T. Santantonio Breakdown of academic impact, for papers by Shigeru Yotsumoto Breakdown of academic impact, for papers by A. Guastadisegni
Rankless by CCL
2026